11.64USD+5.53%Mkt Cap: 657.35M USDP/E: —Last update: 2026-06-01
Climb Bio, Inc., a clinical-stage biotechnology company, focuses on developing therapies to address unmet needs for patients living with immune-mediated diseases. The company's lead product candidate is the budoprutug, a…
Industry Peers
Biotechnology111.39BUSDP/E 26.0
100.62BDKKP/E 19.4
62.97BUSDP/E 14.7
48.39BEURP/E 31.7
44.65BEURP/E 37.2
40.10BUSDP/E 75.3
35.22BUSD—
32.91BSEKP/E 48.6
Indicators:|
Key Statistics
Company
Market Cap657.35M USD
Enterprise Value414.46M USD
Revenue (TTM)—
Gross Profit—
Net Income (TTM)-59.85M USD
Revenue/Share—
Last Price11.64 USD
Fiscal Year EndDec 2025
MR QuarterMar 2026
Employees28
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-9.77
PEG—
EV/EBITDA—
EV/Revenue—
P/S—
P/B3.54
EPS (TTM)-0.77
EPS (Forward)-1.12
52W Range
1.16093% of range12.48
52W High12.48 USD
52W Low1.160 USD
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE-37.30%
ROA-35.68%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-54.36M USD
CapEx (TTM)186.00K USD
FCF Margin—
FCF Yield-5.21%
Net Debt-109.08M USD
Net Debt/EBITDA—
Balance Sheet
Debt/Equity0.00
Current Ratio27.86
Quick Ratio26.91
Book Value/Sh3.100 USD
Cash/Share2.294 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating1.1 (Strong Buy)
Target (Mean)19.77 USD
Target Range15.00 USD – 26.00 USD
# Analysts13
Ownership
Shares Out.57.26M
Float28.06M
Insiders0.37%
Institutions66.46%
Short Interest
Short Ratio2.2d
Short % Float5.16%
Short % Out.3.65%
Shares Short2.09M
Short (prev mo.)1.61M
Technical
SMA 509.059 (+28.5%)
SMA 2004.835 (+140.7%)
Beta—
S&P 52W Chg27.94%
Avg Vol (30d)899.92K
Avg Vol (10d)663.25K
Technical Indicators
RSI (14)55.9
MACD0.5739
MACD Signal0.6250
MACD Hist.-0.0512
BB Upper12.65 USD
BB Middle10.96 USD
BB Lower9.263 USD
BB Width30.93%
ATR (14)0.8041 USD
Vol Ratio (20d)0.33x